Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 7;9:16258. doi: 10.1038/s41598-019-52511-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The proportion of the DENV1 type-specific neutralizing antibody response targeted to the 1F4 epitope is highly variable across the Nicaraguan population in the hospital-based study at 3 and 18 months post-infection. (A) Analysis of the proportion of the DENV1 type-specific response attributable to the 1F4 epitope at 3 and 18 months reveals substantial variability, with individuals displaying a range from high to low proportions of the DENV1 response directed to the 1F4 epitope. (B) Paired analysis where each individual was assigned a color and a symbol to enable visualization of the trajectory of the DENV1 type-specific response to the 1F4 epitope at 3 and 18 months post-infection. (C) Distribution of individuals who gained recognition of the 1F4 epitope between 3 and 18 months (beige), lost recognition (brown) or remained constant (green). (D) The antigenic cartography map positions viruses (DENV1, DENV2 and rDENV2/1 in teal, purple and yellow, respectively) and plasma (open teal squares), with the distance between each virus and plasma derived from its respective neutralizing antibody titer. Each grid square corresponds to a 2-fold dilution in the NT₅₀. From 3 to 18 months post-primary DENV1 infection, the DENV1 and rDENV2/1 titers converge, as indicated by the rDENV2/1 arrow pointing towards DENV1.